HF Session Objectives. Minnesota Pharmacy Legislative Day 2/16/2017. Minnesota Pharmacy Advocacy Agenda: Issue Briefing & Status

Similar documents
Michigan Legislative and Regulatory Pharmacy Initiatives Update

ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]

TITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT

Nebraska s Prescription Drug Monitoring Program Collecting Naloxone and Other Prescription Medications

Public Health Impacts of 2016 West Virginia Legislation

Dispensing and administration of emergency opioid antagonist without a

SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the

MARYLAND BOARD OF PHARMACY

[First Reprint] ASSEMBLY, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 4, 2016

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers

#2015USCA

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

North Dakota Board of Pharmacy

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

LAWS OF ALASKA AN ACT

2017 Legislative Policy Update

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs

US H.R.6 of the 115 th Congress of the United States Session

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

Department of Legislative Services

Michigan Opioid Legislation Hospital Compliance Checklist

Pharmacy Partnership to Improve Patient Outcomes

PROPOSED AMENDMENTS TO HOUSE BILL 3440

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Expanding Immunizing Pharmacist Services in North Carolina

August 30, Washington, DC Washington, DC Dear Chairman Cochran, Chairman Blunt, Vice Chairman Leahy and Ranking Member Murray:

TN Opioid Program. Erica Schlesinger, Pharm.D

For An Act To Be Entitled. Subtitle

Rural Prevention and Treatment of Substance Abuse Toolkit

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Morrison County Community-Based Care Coordination. Our Core Values Reverence Integrity Compassion Excellence

SENATE, No STATE OF NEW JERSEY. 218th LEGISLATURE INTRODUCED FEBRUARY 5, 2018

Opioid Prescribing Improvement Program

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

Minnesota Adult Immunization Initiatives

Article XIX DENTAL HYGIENIST COLLABORATIVE CARE PROGRAM

ASTHO President s Challenge 15 x 15: Reduce Prescription Drug

4/10/2016. Legal & Policy Approaches to Reducing Opioid Poisonings. Overview. Background. Health Directors Legal Conference April 19, 2016

The Dental Therapist Project: Expanding Care to Every Community

Secure Medicine Return in King County, WA. Margaret Shield, Local Hazardous Waste Management Program in King County October 16, 2013

Pathways to Pharmacist Prescriptive Authority

2016 Dr. Douglas H. Kay CPE Symposium

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director

Taxation of E Cigarettes in Minnesota:

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Legislative and Regulatory Update Michael Baxter APhA Director, Regulatory Affairs

January 2017 FEDERAL LAW CURRENT BOARD MEMBERS. June 24, Ben Kesner RPh Executive Director Shelley Bagwell RPh PMP Director.

Taxing E-Cigarettes: the Next (Complicated) Frontier. March 26, 2015

TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown

The Opioid Crisis in Minnesota: On the Ground Approaches. Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP

DEPARTMENT OF HEALTH MEDICAID PAYMENTS FOR DIABETIC TESTING SUPPLIES. Report 2008-S-123 OFFICE OF THE NEW YORK STATE COMPTROLLER

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217

A Modeling Tool for Estimating Practice Based Financial Impact of Adult Immunization. An ACP Quality Connect Program

Legislative Bill Watch As of Thursday March, 13, 2014

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Public Health Applications in Pharmacy

3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott,

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

Idaho DUR Board Meeting Minutes

Improving Adult Vaccination Practices in New York City Pharmacies

Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy. Pharmacists Role 1

Oral Health Provisions in Recent Health Reform: Opportunities for Public-Private Partnerships

FlexRx 6-Tier. SM Pharmacy Benefit Guide

Opioid Epidemic Update & Policy Discussion. Disclosures

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

ADDRESSING THE OPIOID CRISIS:

What Do IACP Members Think?

Legal Considerations for. Immunizations

Fiscal Year 2019 (July 1, 2018 June 30, 2019) Membership Information & Application

IOWA COALITION ON MENTAL HEALTH AND AGING. Policy and Administration Workgroup

A Bill Regular Session, 2015 SENATE BILL 717

The Wisconsin Prescription Drug Monitoring Program

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

COUNTY OF SAN DIEGO AGENDA ITEM

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

Opioid Crisis: HHS Strategy and Advancing Pain Management

Physical Therapist Practice and Ordering X Rays in a Direct Access Model in Wisconsin

Report to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Sub. S.B. 119 As Passed by the Senate

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

Pathways to Pharmacist Prescriptive Authority District 1 and 2 Meeting Groton, CT September 16, Attendance Code. Disclosures 9/1/2017

btute PUBLIC CHAPTER NO. 1039

Agency Report Item 11: Oregon Health Authority Meningitis Vaccination Program in Lane County

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

Confronting the Opioid Crisis at the State Level

Recommendations for Components of Emergency Department Discharge Protocols

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration

National Adult Immunization Plan

Transcription:

Minnesota Pharmacy Advocacy Agenda: Issue Briefing & Status Jill Strykowski, Tammy Bezdicek PATF Co-Chairs Buck Humphrey PATF Lobbyist Jeff Lindoo & Michelle Aytay MPhA Public Affairs Committee Co Chairs Melissa Carlson, PharmD, MSHP Please track and follow HF 1140 https://www.leg.state.mn.us/ Session Objectives List the MPhA, MSHP and Pharmacy Advocacy Task Force's 2017 legislative initiatives. Describe for each initiative the present and future process it will need to go through toward passage. Explain what action is desired for legislator visits. Minnesota Pharmacy Legislative Day 1

Pharmacy Advocacy Task Force (PATF) * note the name change! MN Pharmacists Association MN Society of Health System Pharmacists U of MN College of Pharmacy American Pharmacists Association American Society of Health System Pharmacists National Association of Chain Drug Stores THANK YOU! MN College of Clinical Pharmacy Duluth Area Pharmacists MN Retailers Association MN Board of Pharmacy Legislative Wins 2014 Participation in the initiation, management, modification, and discontinuation of drug therapy according to written protocol or collaborative practice agreement. Collaborative practice: means patient care activities., engaged in by one or more pharmacists who have agreed to work in collaboration with one or more practitioners.. Collaborative practice agreement: means a written signed agreement between one or more pharmacists and one or more practitioners that allows the pharmacist or pharmacists to engage in collaborative practice. Legislative Wins 2015 Immunizations Age Access and reporting requirements Technicians Definition Ratios 2016 Pharmaceutical Waste Extended Medication Supply Prescription Monitoring Program (PMP) Naloxone Minnesota Pharmacy Legislative Day 2

Naloxone and Community Health Boards: Still a significant issue Deaths due to opioid use in MN: 2014:319, 2015:338, 2016 data not in. MN BOP developed an opiate antagonist protocol The Commissioner of Health provides the protocol to Community Health Board consultants. The consultants enter into agreements with pharmacists to prescribe naloxone per protocol. The language is restrictive and does not add value beyond a collaborative practice agreement. MN does not have progressive naloxone prescribing 2017 Legislative Priorities Task Force: Patient Access to Pharmacist Provided Medications Opiate antagonists Travel medications Nicotine replacement products Self - administered hormonal contraceptives Mental Health MPhA Other DHS Pharmacy Reimbursement, following numerous others MSHP Other Technician Tiering Minnesota Pharmacy Legislative Day 3

Please track and follow HF 1140 https://www.leg.state.mn.us/ Patient Access to Pharmacist- Provided Medications Opioid antagonists Travel medications Nicotine replacement products Self administered hormonal contraceptives Our fabulous lobbyist: Buck Humphrey Buck, partner Todd Hill and a team have met with: Sen Abeler Rep Freiberg Lauren Gilchrest Sr Health Cr Policy Sen Benson Rep Liebling Rep Albright Sen Lourey Rep Schultz* Sen Rosen* Sen Hoffman Rep Kiel Sen Lourey* Sen Fishbach Sen Nelson Sen Tomassoni Rep Baker* Sen Jensen Rep Schomacker Rep Peterson* Rep Albright* Rep Hamilton* Rep Franson* Rep Zerwas Rep Murphy* *Indicates Sponsor/Co-Sponsor of PATF bill Minnesota Pharmacy Legislative Day 4

Overview CMS Role in Addressing Public Health Issues January 2017: CMS calls for states to facilitate timely access to drug therapy by expanding scope of pharmacy practice CMS advocates for Standing Orders, Protocols or Collaborative Practice agreements CMS allows states to be flexible to expand access to medications by pharmacists including dispensing based on independently initiated prescriptions. Scope expansion authorized through legislation, or implemented via Dept. of Health and/or Board of Pharmacy CMS calls out: Naloxone, nicotine replacement and tobacco cessation medications, emergency contraception CMS recognizes parallels to influenza vaccine administration. Overview Proposed PATF approach Naloxone, travel meds, self-administered hormonal contraception, smoking cessation Provide via protocol developed by Board of Pharmacy (BOP) BOP will consult with MN Board of Medical Practice and MN Board of Nursing, Commissioner of Health Training program developed by a College of Pharmacy, ACPE CE or approved BOP program Self-administered Hormonal Contraception- Key Points in Draft Language: Pharmacist can prescribe To a person that is at least 18 years of age If under 18, only if a previous prescription from a non-pharmacist practitioner If an approved training program has been completed If protocol is followed A fact sheet and a written record of the contraception is given out Minnesota Pharmacy Legislative Day 5

Self-administered Hormonal Contraception Cont. A pharmacist is prohibited from: Prescribing/dispensing if there is no evidence of a practitioner visit within 3 years following original pharmacist prescription Delegating the prescribing to another person. Self-administered protocol elements: Patient completes a self-screening tool for risk factors Instructions for pharmacists on how to evaluate self-screening tool Pharmacist assessments prior to providing Instructions for contraindications Instructions for referral to PCP or hospital/clinic Additional elements board deems necessary Opiate Antagonist, Travel Medications, Smoking Cessation Must complete an approved training program Must follow a standardized protocol Must provide a fact sheet to patients that includes appropriate method for using. Must provide a record of the medication dispensed. Minnesota Pharmacy Legislative Day 6

NGA/NCSL Scope of Practice Tool Minnesota one of five states Thanks to Kent Bridgeman, Lara Kerwin, Anjoli Punjabi, Tony Olson, Laura Vollmer, Brooke Schooler, Rowan Mahon Legislators have been educated about the tool and its use is expected for any scope of practice change NGA/NCSL Scope of Practice Tool Public Safety and Well Being Access, Cost, Quality, Care Transformation Implications Regulation Education/Professional Qualifications Finance Issues Reimbursement, Fiscal Impact to state,etc. Workforce Impacts Supporters/Opponents Where Are We at in Process? Introduced Monday, February 13 th HF 1140 (Rep Peterson) Must make it out of the House Committees (1 st house of origin) by March 10 th Submitted to the Senate this week (Sen Loureyauthor, Rosen, Abeler, Hoffman) Must pass Senate HHS Reform Committee (2 nd house) by March 17th Once bill has passed both houses, it may need to be conferenced or if identical, bills would go straight to the House and Senate floors for votes. (There are many pitfalls along the way.) Minnesota Pharmacy Legislative Day 7

Other stakeholder meetings MN Medical Association (MMA) Lauren Gilchrist, Governor Dayton s Senior Health Policy aide (Gov would consider signing) MN Nurses Association MN Nurse Practitioners MN Clear Way (anti-tobacco group) MN ACOG MN BOP HF1140 Language Highlights For purposes of sections 151.216; 151.252, subdivision 3; and 151.461, practitioner also means a pharmacist who is prescribing self-administered hormonal contraceptives, nicotine replacement products, opiate antagonists, and travel medications. HF1140 Language Highlights (11) prescribing self-administered hormonal contraceptives, nicotine replacement products, opiate antagonists, and travel medications pursuant to section 152.216 Minnesota Pharmacy Legislative Day 8

HF1140 Language Highlights Sec. 5 Pharmacist Prescribing Self-administered contraceptives 18 or older regardless of prior prescription Under 18 with evidence prior prescription Training program Follow standard protocol Provide patient fact sheet HF1140 Language Highlights Nicotine replacement products, opiate antagonists, and travel medications. (a) A pharmacist is authorized to prescribe nicotine replacement products approved by the federal Food and Drug Administration, opiate antagonists, and travel medications. 6.7 6.8 Key Points Training program Provide patient fact sheet Contraindications, proper use, need for medical follow up, additional information Provide patient written record Minnesota Pharmacy Legislative Day 9

Draft language: Insurance Coverage: All state and federal laws governing insurance coverage of self-administered contraceptive drugs, nicotine replacement products, opiate antagonists, and travel medications shall apply when those products are prescribed by a pharmacist under this section. Board of Pharmacy The board approved the PATF proposed language on February 2 nd. Executive Director can now move beyond technical assistance and can work to support the legislation. Pharmacists as Mental Health Providers Randy Seifert, PharmD Opportunities with HF 737, SF 564 Minnesota Pharmacy Legislative Day 10

Other MPhA Issues Tracking DHS Pharmacy Reimbursement Biosimilars HF 712 Board of Pharmacy Policy Bill Drug refill without a prescription HF443 SF536 Direct injectable drugs reimbursement SF563 Various Opioid-related Bills Mandatory PMP use with all CS SF753 Mandatory collection receptacles HF897 SF795 Limiting time to fill prescriptions SF751 Naloxone standing order compliance HF1136 SF750 Opioid stewardship program SF730 Dispensed meds additional information required HF1135 SF751 Other MSHP Issues Technician Tiering Looking Ahead Overall goal is to move the patient across the continuum of care: focus is on patient care Minnesota Pharmacy Legislative Day 11

On the Horizon. 2018 Priorities & Beyond Scope of Practice Provider status Rule changes Technician tiers Thank You! Minnesota Pharmacy Legislative Day 12